In line with developing novel keloid treatments, we have initiated a clinical study focusing on PIEZO2 expression to establish unique molecular signatures (biomarkers) for monitoring the therapeutic efficacy of PIEZO2‐targeted interventions. The gene discussed is PIEZO2; the disease is keloid.